Literature DB >> 3554470

Transplantation of preneoplastic rat hepatocytes by intraportal injection.

G Saeter, P E Schwarze, J M Nesland, P O Seglen.   

Abstract

Hepatocyte suspensions prepared from inbred male Wistar-Kyoto rats were transplanted to the livers of syngeneic recipients by injection into the portal venous system immediately after partial hepatectomy. Donor cells were labelled with 51Cr in vitro before transplantation. Animals were sacrificed 1 hr, 10 hr, 48 hr, or 1 week later and the liver radioactivity was measured in a gamma counter. Total liver radioactivity declined rapidly during the first 10 hr after transplantation, and then stabilized. After 1 week, 15-20% of the injected radioactivity still remained, indicating that this fraction of the injected cells was retained by the liver. The percentage was unaffected by the number of cells injected. In another experiment, 10(6) hepatocytes from a carcinogen-treated rat were transplanted to syngeneic rats fed 0.05% phenobarbital in the diet. Recipients developed liver carcinomas from 7 weeks after transplantation, and at 5 months 4 out of 5 animals showed severe debility and had large hepatocellular carcinomas. This model generates tumors considerably faster than those previously described, and is well suited for the study of the tumorigenic potential of subclasses of cells in liver carcinogenesis.

Entities:  

Mesh:

Year:  1987        PMID: 3554470     DOI: 10.1177/019262338701500110

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  2 in total

1.  Importance of cytotoxic T lymphocytes in the rejection of transplanted hepatocellular carcinoma.

Authors:  H Kohda; C Sekiya; Y Torimoto; M Mizuno; Y Fujimoto; T Tanaka; A Matsumoto; Y Murazumi; M Ohhira; C Hasebe
Journal:  J Gastroenterol       Date:  1994-06       Impact factor: 7.527

2.  Diploid nature of hepatocellular tumours developing from transplanted preneoplastic liver cells.

Authors:  G Saeter; P E Schwarze; J M Nesland; P O Seglen
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.